CSIMarket Company Name, Ticker, Competitors, else..
 
An2 Therapeutics Inc   (NASDAQ: ANTX)
Other Ticker:  
 
 
Price: $1.4500 $-0.04 -2.685%
Day's High: $1.516 Week Perf: 8.21 %
Day's Low: $ 1.45 30 Day Perf: 33.03 %
Volume (M): 141 52 Wk High: $ 22.22
Volume (M$): $ 204 52 Wk Avg: $5.16
Open: $1.49 52 Wk Low: $0.87



 Market Capitalization (Millions $) 43
 Shares Outstanding (Millions) 30
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -61
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 0

An2 Therapeutics Inc
An2 Therapeutics Inc is a biotechnology company that focuses on developing novel therapies for neurological disorders. They aim to address unmet medical needs in the field of neurology through their innovative drug development programs. The company is dedicated to harnessing the potential of neuroscience research to create effective and safe treatments for patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Their mission is to improve the lives of individuals affected by neurological disorders by delivering transformative therapies.


   Company Address: 1800 El Camino Real Menlo Park 94027 CA
   Company Phone Number: 331-9090   Stock Exchange / Ticker: NASDAQ ANTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        0.08% 
JNJ   -1.8%    
LLY   -1.2%    
MRK        1.91% 
PFE        2.21% 
VTRS        2.21% 
• View Complete Report
   



Business Update

AN2 Therapeutics Implements Stockholder Rights Plan Amid Significant Share Accumulation Implications for Stakeholders

Published Fri, Aug 16 2024 1:10 PM UTC

AbstractAN2 Therapeutics, a biopharmaceutical firm dedicated to developing innovative small molecule therapeutics through its proprietary boron chemistry platform, has adopted a limited duration stockholder rights plan in response to a notable increase in ownership stakes by an investment partner. This article examines the motivations behind this strategic decision, its pot...
Business Update

AN2 Therapeutics Epetraborole Shows Efficacy in Phase 2 Study for MAC Lung Disease, Paving the Way for Fut...

Published Fri, Aug 9 2024 5:10 AM UTC

AN2 Therapeutics Announces Promising Results for Epetraborole in Treating MAC Lung Disease Menlo Park, Calif. AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company renowned for its pioneering efforts in the development of small molecule therapeutics derived from its advanced boron chemistry platform, has made significant strides in the battle against treatme...
An2 Therapeutics Inc

ANTXs Reports Stable Revenue in Third Quarter of 2023, Demonstrating Strong Effort Despite Challenging Market Conditions



An2 Therapeutics Inc, a biotechnology company specializing in the development of therapeutic treatments, recently reported its financial results for the third quarter of 2023. The company experienced both positive and negative changes compared to the previous year. Additionally, its stock performance has fluctuated over the past trading days.
Financial Results:
An2 Therapeutics Inc's earnings per share (EPS) for the third quarter of 2023 showed a slight improvement, decreasing from $-0.81 per share in the previous reporting period to $-0.65 per share. However, this figure remains higher than the EPS of $-0.59 per share recorded a year ago. While the company has shown progress in reducing losses, further improvement is required.
An2 Therapeutics Inc

AN2 Therapeutics Inc Continues to Shine in Stock Market with Exciting Second Quarter Performance

Exciting Prospects in the Stock Market: ANTX Bolsters Confidence for Investors
The stock market is a fascinating arena, filled with ups and downs that keep investors on their toes. It's a platform where businesses strive to make their mark and create opportunities for potential shareholders. One such company that has caught the attention of many observers is ANTX, with its recent performance showcasing a promising trajectory.
During the period from April to June 30, 2023, ANTX experienced a modest increase in its shortfall per share. Although this may raise some eyebrows, it is worth noting that the shortfall per share only increased from $-0.53 to $-0.81 compared to a year ago. Additionally, it also managed to improve from the previous reporting period by decreasing the shortfall from $-0.79 per share.
An2 Therapeutics Inc

1. AN2 Therapeutics Inc Reports Alarming Loss of $-0.79 per Share - Investors Should be Worried2. Lack of Revenue Growth Raises Concerns for AN2 Therapeutics Inc - Shareholders Left Unimpressed

Investors in An2 Therapeutics Inc have reason to be concerned about the recent financial results of the company, which showed significant losses from January to March 31, 2023. The company reported a loss of $-0.79 per share, a significant increase from the $-0.50 per share loss reported in the previous financial reporting period. This is indicative of a worrying trend for shareholders and should give cause for concern.
Furthermore, the revenue for January to March 31, 2023 remained unchanged at $0.00 million from the previous year, despite expectations of growth and improvement for the company. This lack of revenue growth over time is a red flag for investors, as it suggests that the company is struggling to generate increased interest, sales, and traction in the market it operates in.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com